Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 30;12:16415. doi: 10.1038/s41598-022-20186-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

miR342 provides fibroblasts cells with a survival advantage. (A) Transfection of pHFF cells with miR342. Left panel (I): Q-RT-PCR analysis of the relative expression levels of miR-342 after its mimic transfection. The standard Taqman MicroRNA Assays was followed to examine performance of RNU6B (snRNA) endogenous control candidates served as an internal reference. The data summarizes three experiments and expressed as mean ± SD for three experiments. (II) Right Panel: Q- RT-PCR analysis of the relative expression levels of miR342 mimic in the pHFF cells after treatment with various concentrations of that miR-342 mimic (75 ng/μl, 150 ng/μl, 300 ng/μl). * indicates statistical significance. (B). MiR-342 overexpression increases cellular proliferation. 96 h after 150 ng/ $μ$ LmiR mimic 342 and its various controls transfection, we observed a statistically significant increase in the growth of miR-342 overexpressing cells in comparison to cells treated by negative control, untreated fibroblast, or fibroblast + reagent transfection (p < 0.05) By using the SRC assay. The data summarizes three independent experiments and expressed as mean ± SD. (C) The cell cycle status of pHFF cells in response to the ectopic expression of miR342. The DNA content of the cells was measured by flow cytometry. Cells were processed by standard methods using propidium iodide staining of DNA. (I) pHFF cell-cycle profile of cells transfected with transfection reagent. (II) pHFF cell-cycle profile of cells transfected with negative control. (III) pHFF cell-cycle profile of cells transfected with miR-342 mimic (IV) pHFF cell-cycle profile of cells transfected with miR-342 inhibitor (V) pHFF cell-cycle profile of cells transfected with inhibitor negative control (VI) pHFF cell-cycle profile of cells transfected with miR-342 mimic + miR342 inhibitor. (D) Quantification of 7C. Graph displaying differences in cell cycle phases, as determined by flow cytometry analysis, between normal and miR-342 expressing pHFF cells. The data summarizes three independent experiments and expressed as mean ± SD.

miR342 provides fibroblasts cells with a survival advantage. (A) Transfection of pHFF cells with miR342. Left panel (I): Q-RT-PCR analysis of the relative expression levels of miR-342 after its mimic transfection. The standard Taqman MicroRNA Assays was followed to examine performance of RNU6B (snRNA) endogenous control candidates served as an internal reference. The data summarizes three experiments and expressed as mean ± SD for three experiments. (II) Right Panel: Q- RT-PCR analysis of the relative expression levels of miR342 mimic in the pHFF cells after treatment with various concentrations of that miR-342 mimic (75 ng/μl, 150 ng/μl, 300 ng/μl). * indicates statistical significance. (B). MiR-342 overexpression increases cellular proliferation. 96 h after 150 ng/ $μ$ LmiR mimic 342 and its various controls transfection, we observed a statistically significant increase in the growth of miR-342 overexpressing cells in comparison to cells treated by negative control, untreated fibroblast, or fibroblast + reagent transfection (p < 0.05) By using the SRC assay. The data summarizes three independent experiments and expressed as mean ± SD. (C) The cell cycle status of pHFF cells in response to the ectopic expression of miR342. The DNA content of the cells was measured by flow cytometry. Cells were processed by standard methods using propidium iodide staining of DNA. (I) pHFF cell-cycle profile of cells transfected with transfection reagent. (II) pHFF cell-cycle profile of cells transfected with negative control. (III) pHFF cell-cycle profile of cells transfected with miR-342 mimic (IV) pHFF cell-cycle profile of cells transfected with miR-342 inhibitor (V) pHFF cell-cycle profile of cells transfected with inhibitor negative control (VI) pHFF cell-cycle profile of cells transfected with miR-342 mimic + miR342 inhibitor. (D) Quantification of 7C. Graph displaying differences in cell cycle phases, as determined by flow cytometry analysis, between normal and miR-342 expressing pHFF cells. The data summarizes three independent experiments and expressed as mean ± SD.